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Abstract 
The purpose of this project was to determine chronic opioid pain management practices of 
Alaskan Nurse Practitioners (NPs) in primary care, compare them to best practices, and describe 
perceived barriers to evidence-based guideline use.  Participants included NPs in Alaska who 
work in primary care and currently have an active Alaska NP license and Alaska mailing 
address.  This project answered the questions of to what extent primary care NP practices are 
consistent with current Federation of State Medical Boards (2013) guidelines when managing 
chronic non-cancer pain with opioid therapy as well as identified the perceived barriers to 
guideline use.  A cross sectional, descriptive design was used. The principal investigator mailed 
a paper survey to a convenience sample of NPs in Alaska.  Nurse practitioners in Alaska follow 
guidelines when initiating opioid therapy most of the time, with all but three guidelines being 
followed ‘very frequently’ by at least 50% of respondents.  Respondents follow guidelines less 
often when managing opioid therapy with only one guidelines being followed ‘very frequently’ 
by at least 50% of respondents.  Two major barriers to guideline use include resource and 
knowledge barriers. The findings of this project were used to make clinical recommendations for 
improved practice.  
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Introduction 
            Chronic pain affects one-third of adults living in the United States (Johannes, Le, Zhou, 
Johnston, & Dworkin, 2010).  Chronic pain increases with age, with 55 to 64 year olds showing 
the highest prevalence (Johannes et al, 2010).  The American Academy of Pain Medicine 
(AAPM) (2013) recognizes relieving chronic (non-cancer) pain with opioids as a legitimate 
medical practice.  With today’s aging population, providers should be more comfortable and 
competent when prescribing opioids for managing chronic pain.  
 Not surprisingly, the number of those abusing, diverting or selling opioids has increased 
which is consistent with the increased use and prescription of opioids.  The abuse of opioids has 
risen at such a rate that reducing the nonmedical use of prescription pain medications is listed as 
an objective for the Healthy People 2020 initiative (Office of Disease Prevention and Health 
Promotion, 2015). Along with the increase in abuse of opioids, there has also been an increase in 
adverse events and fatalities directly related to opioid use (ASIPP, 2012).  Between 2001 and 
2010, there were 283 hospitalizations due to prescription opioid poisoning or overdose reported 
in Alaska’s Trauma Registry (Alaska Department of Health and Social Services, 2012).  
According to the National Poison Data System there were a total of 1,422 opioid-related 
toxicities between 2001 and 2010 in Alaska (Alaska Department of Health and Social Services, 
2012).  The rising rate of opioid abuse and adverse events causes concerns among providers 
managing prescription opioids. 
Significance to Alaska Advanced Nursing Practice 
 The responsibility of the Advanced Practice Registered Nurse, including NPs, is to 
provide effective pain relief as well as prevent abuse (Alaska Board of Nursing [ABON], 2009).  
In Alaska in 2012, there were 123 drug overdose deaths and 71 (57.7%) of those deaths were due 
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to prescription drugs (Alaska Bureau of Vital Statistics, 2014).  More specifically, 51 (41.5%) of 
drug overdose deaths were due to prescription opioids.  Alaska currently has the 29th highest 
drug overdose rate in the United States, with prescription opioids being the most commonly 
involved drug (Centers for Disease Control, 2013).   
In addition to the increase in abuse, there has been an increase in problems, including 
addiction, due to prescription opioid abuse.  According to the National Survey on Drug Use and 
Health (NSDUH) (2013), 746,000 people received treatment for the abuse of prescription pain 
medication in 2013 compared to 360,000 in 2002.  Not only was there an increase in the abuse 
and treatment of abuse of prescription opioids, the NSDUH results showed of the 4.5 million 
Americans currently abusing prescription opioids, 21.2% obtained them from their provider 
compared to 4.3% who obtained them from a drug dealer (NSDUH, 2013).  This leads to the 
need for increased provider responsibility, as well as increased challenges, when managing 
chronic pain with opioids.   
 Each state determines NP prescriptive authority.  In Alaska, NPs are authorized to 
prescribe, dispense, administer, and procure schedule II to IV controlled substances (Drug 
Enforcement Administration [DEA], 2015).  With a greater ability to prescribe controlled 
substances, NPs in Alaska have a greater responsibility to practice in a safe and evidence based 
manner when managing chronic pain with opioids.  The Advisory Opinion of the Alaska Board 
of Nursing (ABON) (2009) states NPs in Alaska are required to be knowledgeable and 
competent as well as being responsible in the management of acute and chronic pain.  According 
to the Advisory Opinion, the NP is responsible to be educated in the appropriate guidelines, 
recommendations and regulatory policies and procedures when prescribing opioids.  The 
 Running head: OPIOID PRESCRIBING SURVEY OF NURSE PRACTITIONERS 
 
12 
 
prescriptive autonomy of NPs in Alaska requires great responsibility in the management of 
chronic pain with opioids.  
 NPs in Alaska have prescriptive authority to prescribe controlled substances, including 
opioids, therefore t is the duty of the NP to diagnose and evaluate effectiveness of pain 
management.  The NP is responsible to provide effective, evidence based treatment when 
managing chronic pain as well as identifying potential for opioid drug abuse.  Prescription opioid 
poisonings and overdose deaths are a concern in Alaska.   It was unknown to what extent NPs in 
Alaska are following the recommended guidelines when prescribing opioids to manage chronic, 
non-cancer pain in primary care.  The complex nature of managing opioids for chronic pain leads 
to the need to follow specific guidance in regards to best practice.   
Purpose 
 The purpose of this project was to describe the extent to which primary care NP practice 
in Alaska are consistent with current recommended guidelines when treating chronic pain with 
opioids, to describe perceived barriers to following guidelines and to make recommendations for 
improved clinical practice. 
Literature Review 
Increased Use and Abuse 
The prescription of opioids, as well as the sale, use and abuse has been increasing 
steadily.  Contributing to the increase in prescription was the increase in awareness of pain 
management largely due to national policy changes.  In 1996, the American Pain Society 
introduced “Pain as the 5th Vital Sign” and shortly thereafter, the Joint Commission as well as the 
Veterans Health Administration (VHA) adopted policies to raise awareness to the patient’s right 
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to adequate pain relief (VHA, 2000). The VHA released a toolkit in 2000 which discussed 
models for addressing pain including routine pain screening using the 0-to-10 Numeric Rating 
Scale, documenting the pain rating as part of the vital sign record and then completing a 
comprehensive pain assessment and pain for pain management.  It also recommended 
reassessing pain to identify efficacy of intervention (VHA, 2000).  The Joint Commission 
released new standards in 2000 regarding pain assessment and management which were to be 
followed by facilities including ambulatory care, behavioral health care, home care hospitals, 
long-term care, long-term care pharmacies and management behavioral health care organizations 
(National Pharmaceutical Council, 2001).  With the increase in focus on pain management, there 
was also an increase in patient abuse of medications used to treat pain. 
Abuse is defined as the unlawful use of any substance, with misuse defined as the use of 
a controlled substance for reasons other than for which it was legitimately prescribed (Butler, 
Fernandez, Beoit, Budman, & Jamison, 2008; The American Heritage Dictionary, n.d.).  
Manchikanti, Boswell and Hirsch (2013) systematically reviewed the literature on the abuse of 
pain-relief medications with a focus on healthcare costs.  The reviewers found global production 
of morphine increased dramatically, from 168 tons in 1993 to a projected 788 tons in 2012 which 
was more than a fourfold increase.  Similarly, the production of oxycodone rose over 4000%. In 
addition to production, the sales of scheduled medications have increased including opioid 
analgesic sales quadrupling between 1999 and 2010. As expected, increased production and sales 
have paralleled an increase in consumption.  The Pain and Policy Studies Group (PPSG) (2014) 
analyzed legitimate global opioid consumption and found that total morphine equivalent (ME) 
usage per capita (mg/person) increased globally from 3.62 mg/per capita in 1980 to 59.8 mg/per 
capita in 2012. The ME is a metric utilized by the International Narcotics Review Board to 
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provide data combining the six main opioids use to treat pain: fentanyl, hydromorphone, 
methadone, morphine, oxycodone and pethidine (PPSG, 2014). There has been a vast worldwide 
increase in the production, sales and use of opioids.  
Coinciding with production and consumption, the abuse of prescription opioids has risen.  
Young people are among those who are abusing opioids at an increasing rate. According to a 
2009 study investigating various motives of nonmedical prescription drug use, college student 
misuse of prescription drugs was at its highest level when compared to the previous 15 years 
(McCabe, Boyd & Teter, 2009).  Lord, Brevards and Budman (2011) surveyed 527 college 
students to discover motives and attitudes associated with nonmedical use of prescription 
opioids.  This study showed that 61% of young adults had misused prescription opioids and 
prescription stimulants at some point in their lives with the majority of the misuse occurring 
within the past year.  Most of the young adults studied said they first misused prescription 
medications in junior high (8%) or high school (56%).  
The studies on young adult prescription opioid abuse did not specify the source of the 
medication, but according to the NSDUH survey, which includes participants aged 13 years or 
older, more than half (53%) of those surveyed who currently abused pain relievers had obtained 
them from a friend or family member for free (SAMHSA, 2013).  Of those surveyed who 
obtained the prescription pain reliever from a friend or family member, 83.3% reported their 
friend or family member received the medication from only one doctor.  According to a web-
based survey of 27,035 respondents, chronic pain increased with age, with the most prevalent 
age category being 55 to 64 years old (Johannes et al, 2010).  With the aging population, the 
number of adults being treated for chronic pain will continue to increase.  
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Although young people are abusing prescription opioids at increasing rates, they are not 
the only population abusing these medications and suffering consequences from abuse. 
According to the annual mortality data from the Center for Disease Control (CDC) (2011), the 
highest rate of opioid analgesic poisoning deaths occurred in those between 45 and 54 years of 
age.  There were 10.9 deaths per 100,000 resident population in this age range in 2010 compared 
to 2.9 deaths in 1999. When categorized by gender, there were 12 male deaths per 100,000 in the 
45 to 54 year old range compared to 9.8 female deaths. This age range has consistently had the 
highest mortality rate due to opioid pain medications.  This information, along with the studies 
on young adult abuse, illustrate prescription opioid abuse affects several demographics.  
Managing Chronic Pain with Opioids 
While pain specialists accounted for the highest rate of opioid prescriptions (48.6%) in a 
study on opioid prescribing rates from 2007 to 2012, Levy, Paulozzi, Mack and Jones (2015) 
found that primary care providers prescribed the most opioids.  Levy et al. assessed opioid 
prescribing rates by specialty from 2007 to 2012 by grouping and analyzing data from 
Intercontinental Marketing Services (IMS) Health’s National Prescription Audit and found that 
of the 4.2 billion prescriptions filled in U.S.  pharmacies and long-term care facilities, 6.8% (289 
million) were for opioids.  Of the opioid prescriptions filled, 44.5% were ordered by primary 
care practitioners, more so than pain specialists, orthopedic specialists, surgeons or dentists.  
Levy et al. also found a 3.7% overall increase in opioid prescriptions from 2007 to 2012 
according to the audit.  These studies did not differentiate between short or long term opioid 
prescribing practices.  
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Attitudes and Beliefs 
 Franklin, Fulton-Kehoe, Turner, Sullivan, and Wickizer (2013) surveyed providers and 
found there has been an increase in provider concern in regards to chronic pain management, 
especially in the primary care setting, with provider concern increasing from 54% in 2009 to 
72% in 2013. There have been several studies discussing attitudes and beliefs of providers 
regarding opioid prescribing to treat chronic pain which help identify barriers to best practice.  
Hooten and Bruce (2011) surveyed 128 healthcare providers to assess beliefs and attitudes 
regarding managing chronic pain with prescription opioids. Of those surveyed, 58% said they 
were likely to prescribe opioids for chronic pain but indicated prescribing opioids had the 
potential to dramatically add to the complexity of caring for the patient.  The researchers 
identified education gaps in regards to opioid prescribing by healthcare providers.  In addition to 
attitudes and beliefs, there has been research to identify provider knowledge and views regarding 
chronic pain management with opioids.  Jamison, Sheehan, Scanlan, Matthews and Ross (2014) 
surveyed primary care providers (n=56) to determine their knowledge about opioids, thoughts 
about drug abuse and thoughts about managing chronic pain with opioids.  Of those surveyed, 
the majority (84%) had concerns when managing opioids for chronic pain.  More specifically, 
providers felt managing opioids for chronic pain was stressful with 82% of those surveyed 
having concerns about addiction.  Of the providers who responded, 46% indicated they were not 
adequately trained in prescribing opioids.  This study also found younger providers reported less 
confidence and more concerns about opioid dependency than older providers.   By assessing 
attitudes and beliefs of providers managing chronic pain with opioids, knowledge as well as 
confidence barriers to best practice were identified. 
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Prescription Drug Monitoring Programs 
Prescription Drug Monitoring Programs (PDMPs) are databases that store information on 
controlled substances so prescribers can access the data to deter abuse, doctor shopping and 
diversion (Worley, 2012).  PDMPs are managed at the state level with each state being 
responsible for creating and funding their state’s program. As of 2014, every state had a PDMP 
except for Missouri which had pending legislation (The National Alliance for Model State Drug 
Laws, 2014).  Accessing and utilizing PDMPs are recommended by many guidelines and there 
have been several studies done to assess perceptions and use of PDMPs. 
Kelly (2013) surveyed 141 Florida Emergency Room physicians asking questions 
regarding management strategies when prescribing controlled substances and accessing the 
state’s PDMP.  The researcher concluded there was a clear indication for more education and 
special training in the management of narcotic abuse.  Kelley (2013) found there was poor 
utilization of tools including patient history, physical exam, the state’s PDMP, and drug screens 
to identify misuse and abuse. This study highlights the need for additional education as well as 
resources when managing chronic pain with opioids. 
Dowler (2013) assessed provider’s perception of Oregon’s PDMP by surveying those 
who have access, including physicians, NPs, dentists and pharmacists. Respondents provided 
feedback on the usefulness of the state’s PDMP as well as the website. Most of the suggestions 
for additions to the website reported by those surveyed pertained to interventions once the PDMP 
had been utilized such as resources for substance abuse treatment, making referrals as well as 
providing recommendations once patients with substance abuse problems had been identified.  In 
addition to identifying a patient who is potentially misusing drugs, at least 80% of those 
surveyed felt potential resources such as guidelines for pain management as well as guidance 
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with patient interaction while the provider is using the PDMP would be useful.  Overall, 
education as well as substance abuse resources were identified barriers when utilizing the PDMP. 
Guideline Utilization  
 Several organizations have created evidence-based guidelines and recommendations to 
promote safe opioid prescribing practices as well as preventing or identifying abuse.  Franklin et 
al. (2013) surveyed 856 providers in Spokane, Washington on the changes in practice as well as 
the use of support tools when prescribing opioids for non-malignant pain.  Only 40.1% of 
advanced practice nurses surveyed, including NPs, were aware of opioid dosing guidelines 
compared to 70.9% of physicians.  Respondents identified limited access to pain specialists as a 
barrier to guideline adherence, even in the largest city in eastern Washington 45% of respondents 
reported a limited ability to obtain a consultation to a pain specialist.  The researchers identified 
that providers who practiced in a healthcare facility with specific opioid prescribing guidelines 
were less likely to completely stop prescribing opioids as a practitioner and were less concerned 
about problems that can occur when prescribing.   
 Rather than surveying providers, Sekhon, Aminjavahery, Davis, Roswarski and Robinette 
(2013) reviewed patient charts to determine compliance with opioid treatment guidelines in 
primary care at a Veterans Affairs Medical Center (VAMC).  Of the 800 patient charts reviewed, 
the researchers found provider practices varied widely with respect to the use of opioid 
management guidelines.  Veterans Affairs/Department of Defense (2010) guidelines include 
developing written opioid pain care agreements and at least one urine drug screen at some point 
during treatment.  Of the charts reviewed, only half of the patients had signed written agreements 
and had at least one drug screen at some point during treatment.  The researchers also found 
when a patient had a written agreement in their health records, they were at a lower risk of 
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displaying aberrant drug related behavior (OR 0.81, P < .01) (Sekhon et al., 2013).  Of the 
patients who had urine drug screens, drug panels which included oxycodone testing were only 
selected 53% of the time.  Sekhon et al. postulated this may be due to a lack of knowledge that 
standard urine drug screens do not include oxycodone and that it has to be ordered separately, 
although there was no data to support this assumption.  The patients who were found to have 
positive urine drug screens for illicit drugs or negative urine drug screens when prescribed 
opioids often did not have intervention with only 28% having documented discontinuation or 
discussion with their provider.  The researchers concluded there was a need for further education 
for primary providers to enhance guideline use adherence.  Although there are tools and 
guidelines available, education appears as a common barrier identified by much of the research 
discussed.  
Evidence-Based Practice 
 Many of the available guidelines for treating chronic pain with opioids in primary care 
setting include similar recommendations, although there are some areas of inconsistency.  The 
majority of guidelines are specific to long-term, or chronic opioid use which is defined as the use 
of opioid therapy for 90 days or longer (American Society of Interventional Pain Physicians 
[ASIPP], 2012).  Alaska does not have a formal medical or nursing board position focused on the 
use of controlled substances in the treatment of chronic pain (Bolen, 2008).  The Alaska Board of 
Nursing (ABON) has adopted the Federation of State Medical Boards (FSMB) Policy Statement 
on the use of controlled substances to treat chronic pain (Bolen, 2008).  The most recent 
Advisory Opinion (ABON, 2009) on the use of controlled substances for pain management 
discusses the accepted standards as mentioned in the FSMB (2013) Policy Statement.  ABON 
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Advisory Opinions do not constitute mandatory practices standards, rather they are official 
opinions and recommendations to guide nursing practice.  
 The FSMB (2013) provides a detailed model policy including steps to initiating opioid 
therapy as well as management of therapy (Table A-1). Prior to starting therapy, the provider 
must identify risk factors by obtaining a thorough medical, psychological and substance abuse 
history. Obtaining written informed consent and treatment agreement prior to beginning opioid 
therapy is also recommended. The model policy states a treatment plan should have obtainable 
goals and an opioid trial should be implemented at the initiation of therapy. The “Five As” of 
chronic pain management should be monitored throughout treatment (FSMB, 2013).  The Five 
As include: reduction in pain (Analgesia), improvement in level of function (Activity), presence 
of significant adverse effects (Adverse effects), evidence of aberrant substance-related behaviors 
(Aberrant behaviors), and mood of patient (Affect). During management of treatment, consistent 
monitoring should be maintained including assessment of patient and utilizing tools such as the 
PDMP and the “Five As” (FSMB, 2013). Lastly, providers should refer patients to a pain, 
psychiatry, addiction or mental health specialist as appropriate. 
 The American Association of Nurse Practitioners does not provide guidelines on the use 
of opioids to manage patients with chronic pain, rather they recommend the American Academy 
of Pain Medicine (AAPM) (2013) guidelines (American Association of Nurse Practitioners, 
2015).  The AAPM (2013) statement on the use of opioids for the treatment of chronic pain 
endorses interventions to decrease the risk of drug abuse including urine or blood drug screening, 
frequent follow up, pill counting as well as periodic review of the state’s PDMP where available.  
Obtaining an initial pain history from the patient as well as baseline drug screening may be 
appropriate according to AAPM guidelines.  Random drug screening and pill counts help 
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monitor compliance of treatment as well as consistent follow up visits. Lastly, the AAPM 
recommends consultation with a pain specialist when needed, especially if the patient has a 
history of addiction or psychiatric disorders. 
  The American Society of Interventional Pain Physicians (ASIPP) (2015) specializes in 
pain intervention and provides evidence-based practice guidelines. Consistent with FSMB (2013) 
and AAMP (2013) guidelines, ASIPP (2012) guidelines recommend identifying appropriate 
physical and psychological diagnosis if available prior to initiating therapy. The ASIPP 
guidelines are lengthier, and include recommendations that are not in FSMB (2013) or AAPM 
(2013) guidelines.  The additional ASIPP (2012) recommendations include advising caution in 
ordering imaging or other evaluations as to minimize the potential for increased fear, activity 
restriction or requests for more opioids from the patient.  Patients should be divided into one of 
three categories, low, medium or high potential for abuse based on criteria in the guidelines.  
Depending on the patient’s risk category, the opioid dose as well as use and frequency of urine 
drug screening and frequency of PDMP access is determined based on an algorithm developed 
by ASIPP (2012).   
 Guidelines from the three organizations discussed above all contain several consistent 
recommendations for initiating and monitoring the treatment of chronic pain with opioids in 
primary care (see Table 1).  Thorough evaluation and assessment of patients at initiation of 
therapy including past medical and psychiatric history as well as history of substance abuse is 
advised by all three organizations.  Each guideline strongly emphasizes the need to establish and 
identify current and past risks for complications of initiating opioid therapy.  Once the history is 
obtained, all three organizations advise providers to assess for contraindications, establish 
treatment goals and initiate an opioid trial once opioid therapy has been decided.  Once opioid 
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therapy has been started, all three guidelines advise frequent follow up and monitoring by using 
various tools including urine drug screening, pill counts, the FSBM (2013) “Five A’s” and/or 
accessing the state’s PDMP.  In order to manage opioid therapy safely, all three organizations 
recommend thorough documentation throughout treatment.  Lastly, consultation to specialists 
when needed are encouraged by all three organizations.   
Table 1 
 
Comparison of Opioid Prescribing Guidelines 
 
Guideline American Academy of 
Pain Medicine1 
Federation of State 
Medical Boards2 
American Society of 
Interventional Pain 
Physicians3 
Health history Strongly recommends* Strongly recommends  Strongly recommends 
Mental health history Strongly recommends Strongly recommends Strongly recommends 
Substance abuse history Strongly recommends Strongly recommends Strongly recommends 
Opioid Screening Tools No specific 
recommendation 
Recommends** Recommends 
Assess for contraindications 
or risks prior to initiation  
Strongly recommends Strongly recommends Strongly recommends 
Treatment goals Strongly recommends Strongly recommends Strongly recommends 
Treatment contract No specific 
recommendation 
Strongly recommends Strongly recommends 
Opioid trial Strongly recommends Strongly recommends Recommends 
Frequent review of progress 
and assessment for abuse 
including accessing state’s 
Prescription Drug 
Monitoring Program or 
“Five A’s” 
Strongly recommends; 
access PDMP 
Strongly recommends; 
access PDMP and use 
“Five A’s” 
Strongly recommends; 
access PDMP 
Urine Drug Test Recommends Recommends Strongly recommends 
Pill count Recommends Recommends No specific 
recommendation 
Initiate bowel regimen when 
indicated 
No specific 
recommendation 
No specific 
recommendation 
Strongly recommends 
Consultation when 
necessary 
Strongly recommends Strongly recommends Strongly recommends 
Monitoring for need/ability 
to discontinue opioid 
therapy 
No specific 
recommendation 
Strongly recommends No specific 
recommendation 
Thorough documentation Strongly recommends Strongly recommends Strongly recommends 
*Recommendations are identified as strongly recommended if the guideline is listed as something that must or 
should be done.   
**Recommendations are identified as recommended if the guideline is listed as something that may be 
useful/helpful. 
1. Adapted from American Academy of Pain Medicine, 2013  
2. Adapted from Federation of State Medical Boards, 2013 
3. Adapted from American Society of Interventional Pain Physicians, 2012 
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Research Questions 
1. To what extent are primary care NP practices consistent with current FSMB (2013) 
guidelines when managing chronic non-cancer pain with opioid therapy? 
2. What are the perceived barriers to primary care NP guideline use when managing chronic 
pain with opioids? 
Methods 
 This project used a cross-sectional, descriptive design.  The principal investigator 
recruited a convenience sample of NPs by downloading the list of current Alaska NP license 
holders as well as their mailing address from the ABON public use website.   
Measure 
 A paper survey measured Alaska NP practices and barriers regarding the use of current 
guidelines on the treatment of chronic pain with opioids (Appendix B).  The researcher-
developed survey contained 22 items (20 close-ended, five-point Likert scale items and two 
open-ended items).  Guidelines from the FSMB (2013) were used in the survey as these are 
recommended as best practice by the ABON (2008).  NPs were asked the frequency of use of 
key practices recommended by the FSMB (2013). The guidelines were divided into two 
subcategories: initiation of opioid therapy and management of opioid therapy. Questions 
regarding use when prescribing opioids for chronic pain used a five-point Likert scale consisting 
of five response choices: very frequently, frequently, occasionally, rarely and very rarely. The 
question regarding barriers to guideline use allowed the respondent to select all that apply as well 
as space to add additional barriers not mentioned in survey.  The open-ended question asked for 
further thoughts regarding opioid prescribing practices. The survey also included five close-
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ended questions to collect demographic data on respondents.  Demographic questions were used 
to exclude several subgroups from the survey. Respondents were asked to indicate their- age, 
years practicing as a licensed NP, zip code, practice setting (on or off road system) and specialty.  
To establish readability and face validity, the survey was pilot-tested with a group of 10 NPs and 
NP student peers in Alaska after this project was approved. 
Inclusion and Exclusion Criteria 
 The sample included NPs currently licensed to practice in Alaska with an Alaska 
mailing address, as of June 9, 2015,  615 NPs met these criteria.  NPs who worked in a pain 
management practice or hospice/palliative care were excluded as this survey was aimed at 
primary care practitioner management of chronic pain.  NPs who work in oncology were also 
excluded as the guidelines apply to non-malignant chronic pain management.  
Data Analysis 
 The data was analyzed using the Statistical Package for the Social Sciences Version 23 
(SPSS, 23).  Survey responses were summarized using descriptive statistics.  The majority of 
survey responses were ordinal level of measurement, with the exception of the demographic and 
barrier survey items which were nominal.  The open-ended question were analyzed to identify 
any recurring themes within the responses by using inductive content analysis as described by 
Elo and Kyngas (2007). Themes were identified by open coding, creating categories and 
abstraction.  
Discussion of Rights of Human Subjects and the Consent/Review Process 
The University of Alaska’s Institutional Review Board reviewed and approved this project under 
exempt status.  Respondent consent was implied by the returning of the survey.  Instructions and 
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an explanation of the project were included in a cover page with the survey, as well as a two-
week return request (Appendix A).  There was no cost or risk to respondents.  There was no 
identifying information collected with the survey.   
Results 
Respondents 
  There were 179 surveys returned, 169 meeting the inclusion criteria, yielding a 
response rate of 27.5%. Of those who responded, 22.9% (n=41) were 40 years or younger, 48% 
(n=86) were between the ages of 41 and 60, 26.8% (n=48) were 61 years old or greater and four 
respondents did not list age.  When asked about years of practice, 23.7% (n=42) practiced five 
years or less, 34.8% (n=62) practiced between five and half years and fifteen, 26.3% (n=47) 
practiced 16 to 25 years and 15.4% (n=27) practiced 26 years or greater. The average years of 
practice of respondents was 14.5 years. 
 When asked about specialty area of practice, 5.5% (n=10) reported pain specialty, 
oncology, hospice or palliative care, therefore excluding their responses regarding guideline 
adherence. Primary adult care was the largest group represented with 25.5% (n=45), followed by 
family practice, 16.2% (n=29).  Mental health represented 9.5% (n=17) of respondents followed 
by women’s health (including midwifery), 13.97% (n=25). Emergency/urgent care represented 
4.5% (n=8) of responses and pediatrics represented 4.47% (n=10).  The remaining 19.5% (n=35) 
of respondents listed areas of practice which were represented by two or less respondents each 
and were therefore combined into one category (Figure 1).  
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Figure 1. Primary area of practice of respondents  
 In regards to location, 84.4% (n=151) of respondents said they were on the road system, 
12.3% (n=22) were off the road system, 2.2% (n=4) responded both on and off the road system 
and two respondents did not answer (Figure 2).  The most common location was the Anchorage 
bowl area, representing 56.98% (n=102), which also included Eagle River, Chugiak and 
Girdwood.  Matanuska- Susitna valley and southeast Alaska each represented 11.17% (n=20) of 
respondent answers. There were 12 (6.7%) respondents who listed the Fairbanks area as their zip 
code. The Kenai Peninsula was chosen by 3.91% (n=7) of respondents and the remaining 
Southwest region was chosen by 5.03% (n=9) of respondents.  There were two (1.12%) 
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responses from South-central Alaska that were not in the Anchorage bowl or Matanuska-Susitna 
Valley and there were two (1.12%) responses from Washington.  Three respondents did not list 
zip code (Figure 3).   
 
Figure 2. Location of respondents in regards to road system 
 
Figure 3. Location of respondents 
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Barriers 
  All respondents, whether or not they managed chronic pain with opioids, were 
asked to identify their perceived barriers to guideline use. Of those who responded, almost half 
(41.9%, n=75) listed being unfamiliar with current guidelines as a barrier. The following most 
commonly listed barriers were feeling unqualified to address pain management (33.5%, n=60), 
unfamiliar with the Alaska Prescription Drug Monitoring Program (PDMP) (32.4%, n=58), and 
unfamiliar with how to access/use the PDMP (30.7%, n=55).  In addition to barriers regarding 
knowledge of guidelines and PDMP, 29.6% (n=53) of respondents listed “lack of confidence in 
addressing potential prescription drug abuse” as a barrier to guideline use. Respondents selected 
“being unsure when to refer to specialist” 16.2% (n=29) of the time. 
 In regards to resource barriers, 27.9% (n=50) listed not having enough time during visit 
as a barrier, 19% (n=34) listed lack of patient access to a specialist due to location as a barrier 
and 14% (n=25) of respondents listed inadequate patient insurance as a barrier to guidelines use.  
Fear of offending patient was selected by 8.9% (n=25) of respondents and fear of patient going 
to a different provider was selected by 3.4% (n=6) of respondents.   
Guideline Use 
 Of the 169 respondents who met inclusion criteria, 32.5% (n=55) stated they prescribe 
opioids to manage chronic pain while two respondents did not answer and one answered both yes 
and no, but proceeded to provide answers for guideline adherence in practice. The Likert scale 
questions were divided into two categories: initiating opioid therapy and managing opioid 
therapy.  In regards to initiating opioid therapy, the majority of respondents obtained a thorough 
history most of the time including: obtaining a thorough medical history (n=52, M=4.96), 
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obtaining a thorough mental health history (n=52, M=4.63), and obtaining a substance abuse 
history (n=52, M=4.73).  Respondents also assessed for contraindications and risks of initiating 
therapy (n=52, M=4.87) and initiate an opioid trail with specific goals (n=50, M=4.22) most of 
the time.  Respondents consulted with specialist when a risk for addiction had been identified 
(n=49, M=3.59) and obtained a written treatment agreement (n=49, M=3.71) less frequently but 
still above the median score.  Respondents were least likely to have obtained written informed 
consent (n=48, M=3.52) and reviewed patient history using the Alaska PDMP (n=48, M=3.54) 
consistently (Figure 4).  
 
Figure 4. NP guideline adherence when initiating opioids for chronic pain 
 When managing chronic pain with opioid therapy, respondents were most likely to have 
monitored for the need or ability to discontinue therapy (n=57, M=4.25), followed by referring 
for consultation from a pain, psychiatric, addiction or other specialist (n=57, M=3.77).  Although 
still scoring above the median, respondents were less likely to have assessed results of chronic 
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opioid therapy using the “5 A’s” (n=57, M=3.30).  The guideline that was least likely to be used 
when managing chronic pain with opioids is to have obtained the patient’s prescription history 
from the Alaska PDMP (n=58, M=3.16) (Figure 5).  
 
Figure 5. NP guideline adherence when managing chronic pain with opioids 
 Respondents were asked to select ‘no’, ‘only with some patients’ or ‘yes’ if they 
periodically performed urine or blood testing as well as periodically counted the patient’s pills 
when managing chronic pain with opioids.  Both questions yielded responses below the median, 
with periodic pill counting (n=58, M=1.11) occurring less frequently than periodically 
performing urine or blood testing (n=58, M=1.47) (Figure 6). 
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Figure 6. NP guideline adherence of periodic testing when managing chronic pain with opioids 
  
 Respondents were also asked to select ‘no’ or ‘yes’ in regards to providing 
documentation recommended in the guidelines when managing chronic pain with opioids. 
Respondents were most likely to document medical history (n=58, M=.98), exam (n=58, M=.93), 
and all prescription orders (n=58, M=.93).  Most respondents were also likely to document 
treatment descriptions (n=58, M=.91), instructions given to patients (n=58, M=.88), and lab 
history (n=58, M=.83).  Respondents were less likely to document notes on 
evaluations/consultations with specialists (n=58, M=.81) and written instructions for use (n=58, 
M=.72), although responses were still above the median.  The components of documentation 
respondents were least likely to include were authorization for release of information to other 
treatment providers (n=58, M=.52) and risk assessment results (n=58, M=.45). 
Open-ended Responses 
  Respondents, regardless of whether or not they managed chronic pain with 
opioids, were to list additional barriers to guideline use and to provide any additional thoughts 
they may have regarding this topic. Due to the vast overlap in responses, the two questions were 
combined to provide a succinct collection of themes which emerged during analysis.   
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 Clinical setting.  The most common theme (n=21) was that managing chronic pain with 
opioids was not within the scope of practice of the respondent’s setting, for example, their 
clinical setting had a policy to not manage chronic pain or they did not treat patients with chronic 
pain in their practice or specialty. Typical responses included “I never prescribe pain meds in my 
practice” and “clinic policy is to use opioids for acute pain only”.   
 Pain specialist.  Barriers regarding pain specialists was multifactorial according to 
several respondents (n=12).  Among the barriers listed were cost of specialist and inadequate 
access to specialists with one respondent stating “lack of pain specialists who will take 
Medicare/Medicaid hinders my referral abilities”.  Others claim specialists will not take patient, 
stating “[the patient has] poor compliance with ‘pain specialists’ and end up getting ‘fired’ by the 
pain specialist causing a dilemma of needing pain management but no providers willing to treat”.  
Additionally, respondents mentioned patient aversion to being seen by pain specialist, stating 
“patient doesn’t want pain specialist- afraid of going to office especially if they are not ‘one of 
them’”.  Respondents stated they try to get patients to see specialists when available, especially if 
they are at a high risk of addiction.  One respondent stated they only manage chronic pain if the 
patient has been evaluated by a pain specialist and “are well known and current long term 
patients in my practice”, indicating a need for collaborate effort in regards to chronic pain 
management.  
 Uncomfortable/challenge to manage chronic pain.  Of the listed barriers and additional 
thoughts, nine respondents claimed they felt uncomfortable or disliked managing chronic pain 
with opioids. Responses included “challenging! Would prefer not to have to do”, “time 
consuming” and “appropriate management is difficult”.  
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 Aberrant patient behavior/fear of litigation.  Identified as a barrier by eight 
respondents was the concern of abuse or aberrant behavior by the patient, as well as the general 
overuse of opioid pain medications. Respondents listed “drug-seeking patients” and “concerns 
that opioids may be sold for higher street value (instead of being taken as intended)” as barrier.  
One respondent stated “far too many end up on narcotics, they lie, they sell their drugs and we 
are supposed to buy into it. There is way too much abuse and the medical profession teaches to 
buy into it”.  Others have chosen not to manage chronic pain due to time constraints related to 
drug-seeking.  In regards to litigation, one respondent wrote “fear of having license targeted and 
taken away due to being accused of running a pill mill. Litigation of patient, family, overdose, 
suicide using opioids” in the barriers section of the survey.  
 Complication/comorbidities.  Seven respondents mentioned comorbid conditions which 
make managing chronic pain more complex in regards to properly obtaining a history from 
patient or the difficulty in coordinating care.  Examples of comorbidities respondents listed as 
complicating care include when chronic pain patients become pregnant, stating the primary 
provider of the pain medications “do not want involvement during pregnancy which puts our 
patients and providers in a bad spot” or they only manage during illness specific to their specialty 
such as Lyme disease treatment.  Another example stated by a respondent was the increased 
tolerance to pain medications a patient may have and how this complicates care if the patient has 
surgery or suffers a trauma.   
 Refer to others.  In addition to not managing due to practice policy or setting, seven 
respondents stated they refer to other providers when presented with a patient who has chronic 
pain.  Reasons listed were their current practice setting was not appropriate to manage chronic 
pain or due to a lack of knowledge or experience.  One respondent whose primary area of 
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practice is emergency/urgent care stated “[I] defer to PCP [primary care provider] since pain 
contract needs to be established so PCP can dispense no more than 30 days of pain meds, urine 
test sometimes used to ensure no other drugs used” while one women’s health care provided said 
“[I] decided not to get my DEA number years ago. Refer to another HCP [healthcare provider] if 
this an issue”. Referring to medical doctor was listed by two respondents stating “I only manage 
a very small number of chronic pain patients, after three months of pain I transfer care to MD in 
our office who routinely manages chronic pain.”  One respondent listed lack of knowledge as a 
barrier as a reason to refer, stating: 
I frequently don’t feel comfortable with the pathophysiology versus subjective experience 
i.e. when patient complains of increased pain and requests more opioids-is it a complaint 
that needs further eval[ulation] (ultrasound, CT, etc.) vs a psychogenic reaction and 
therefore I refer them to MD.   
 Insurance.  Another common theme mentioned (n=6) was insurance as a barrier to 
manage chronic pain with opioids. Respondents claimed insurance companies did not cover 
medications or that referrals were denied by Medicaid. Others stated there was a lack of 
insurance for alternative therapies such as massage or acupuncture. One respondent stated “we 
do always try to get these patients to specialists, but most recently all of these referrals have been 
denies by Medicaid”.  
 Providing coverage for previous provider.  Another theme that emerged was providers 
continuing to manage chronic pain for a patient previously initiated by another provider (n=5).  
Of those respondents who stated they continue existing treatment plans, two claimed they did not 
like managing chronic pain, but “people who are on don’t want to stop and as their provider I 
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continue old prescription even if I don’t like it- I rarely initiate”. A couple of respondents stated 
they work as locum tenants and continue treatment plans initiated by others.    
 Alternative therapies.  Offering alternative or complementary modalities for pain 
management was listed by five respondents.  Physical therapy, steam, topicals, massage, 
counseling and osteopathic manipulation were among the alternative therapies mentioned.  One 
respondent states they rarely use opioid therapy for chronic pain and it is only used once all other 
avenues have failed while another states “opioids are not the drugs of choice for chronic pain (or 
shouldn’t be in my and many others opinion)”.    
 Training and education.  There was a theme of education and a need for additional 
certification mentioned by five respondents.  Respondents claimed if providers are prescribing 
opioids, they should follow current guidelines, need certifications and another mentioned 
providers attending a CME [continuing medication education] on narcotic prescription, stating 
“it puts the fear of God in you if you do not document correctly and what can happen if DEA 
comes knocking.”  Others mentioned interest in using the PDMP and learning how to manage 
chronic pain.  
Discussion  
 The average years of practice of respondents was 14.5 years, which is one year higher 
than a 2015 study of 100 Alaska NPs which listed 13.5 years as the average years of practice 
(Alaska Nurse Practitioner Association, 2015). When comparing regional location of respondents 
to the total number of surveys mailed (n=615), the greatest area of variance was between the 
Kenai Peninsula region representing 6.7% (n=7) of respondents but only 5.52% (n=48) of mailed 
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surveys.  Based on the similar average years of practice as well as similar distribution regionally, 
the sample is fairly representative of the Alaska NP population.   
 The majority of respondents who manage chronic pain are following guidelines most of 
the time when initiating therapy with all but three of the nine guidelines being used very 
frequently by at least 50% of respondents. The lack of adherence to guidelines involving the 
state’s PDMP may be due to the fact that the program is still very new to the state of Alaska, as 
the program was launched in 2013.  Regarding consultation with specialists, providers may not 
know when to consult or refer due to a knowledge barrier of guidelines for chronic opioid use.    
Fewer respondents are following guidelines consistently when managing therapy with only one 
of the four guidelines being followed ‘very frequently’ by at least 50% of respondents.  The 
decrease in guideline adherence when managing may be attributed to providers managing 
chronic pain during acute or limited settings or respondents are covering for other providers.  
Managing chronic pain requires the use of tools such as the PDMP and “Five A’s” so if 
providers lack the knowledge of how to use these tools, this may attribute to the decrease in 
guideline adherence.  Respondents perform periodic urine or blood drug testing more often than 
periodic pill counting, with pill counting occurring less than half of the time. These results are 
similar to those from Sekhon et al (2013) who found that written agreements and at least one 
drug screening were done only half of the time.  The only documentation component of the 
recommended guidelines not followed by at least 50% of respondents was documenting risk 
assessment scores, which illustrates that providers are documenting chronic pain management 
most of the time.   
 The most common barriers listed by respondents can been divided into two categories: 
knowledge deficit and resource deficit.  Knowledge deficit barriers included being unfamiliar 
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with current guidelines or how to use or access the PDMP.  This is consistent with Sekhon et al 
(2013) who concluded that further education is needed for primary care providers in order to 
increase guideline use.  These findings are also consistent with the Franklin et al (2013) study 
that identified a lack of knowledge regarding available guidelines.  Sekhon et al discussed the 
lack of proper drug screen utilization also potentially being a knowledge barrier.  Additional 
common knowledge deficit barriers identified by respondents were feeling unqualified to 
addressed pain management or a lack of confidence to address abuse.  These results are 
consistent with Dowler (2013) who found that providers would like to have resources for 
substance abuse treatment as well as recommendations once substance abuse has been identified 
when asked to make recommendations for the Oregon PDMP. Additionally, Sekhon et al found 
that documented intervention once a patient failed a drug screen was only done 28% of the time, 
and this may be attributed to the lack of confidence to address abuse.  
 In regards to resource barriers listed by respondents, lack of time, no patient access to 
specialist due to location or inadequate patient insurance were the most commonly listed 
resource barriers. Limited access to specialists was also listed as a barrier to guideline adherence 
by Franklin et al (2013) in their study of Washington providers.  
 The majority of respondents who manage chronic pain with opioids are following 
recommended guidelines most of the time, with the greatest adherence at the initiation of 
therapy.  There is a decrease in adherence when managing chronic pain with opioids which may 
be due to the knowledge and resource barriers listed by respondents.  Among the most common 
resource barriers listed were pain specialist access, insurance barriers and lack of time.  
Knowledge barriers included lack of knowledge regarding PDMP use, lack of guideline 
knowledge and lack of confidence managing chronic pain with opioids.   
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Implications 
 The results of the survey provided information on current practices regarding pain 
management and to what extent those practices are consistent with current guidelines.  
Knowledge barriers were one of the most common themes identified, therefore more 
opportunities for Alaska NPs to learn from educational offerings should be made available to 
Alaska NPs to increase guideline use when managing chronic pain with opioids. Alaska’s PDMP 
should also provide resources and education regarding use and tools to increase awareness and 
accessibility of this asset.  Funding should be made available for providers to gain access to 
resources for patients, including continued state coverage of the PDMP and coverage of patient 
services that may not be reimbursed by insurance.  
Dissemination  
 A poster presentation of the results was presented at the Advanced Practice Registered 
Nurse Alliance conference focusing on opioid therapy on January 9, 2016 which led to 
discussion regarding awareness of guidelines with several attendees.  I will further disseminate 
my project findings by submitting to present my poster at the Alaska NP Conference in 
September of 2016.   At the conference I will have flyers on hand which will have resources 
listed regarding online educational opportunities that will be available for attendees (Appendix 
C).  These resources are aimed to increase knowledge and confidence in providers when 
managing chronic pain with opioids. This flyer will also be sent to the Alaska Nurse Practitioner 
Association to be posted to their website.  A copy of this project will be sent to the Alaska 
PDMP for review and consideration.  
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Appendix A 
 
Model Policy for Initiation Therapy 
Table A-1 
 
 FSMB (2013) Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain 
 
Complete 
assessment of 
patient 
history 
 For every patient the initial work-up should include a systems review 
and relevant physical examination, as well as laboratory investigations 
as indicated.  
 Social and vocational assessment is useful in identifying supports and 
obstacles to treatment and rehabilitation. 
 Assessment of the patient’s personal and family history of alcohol or 
drug abuse and relative risk for medication misuse or abuse also 
should be part of the initial evaluation. 
 All patients should be screened for depression and other mental health 
disorders, as part of risk evaluation. 
 Use of a validated screen tool (such as the Screener and Opioid 
Assessment for Patients with Pain or the Opioid Risk Tool), or other 
validated screening tools, can save time in collecting and evaluating 
the information and determining the patient’s level of risk.  
Patients with 
substance 
abuse 
disorders 
 Patients who have a history of substance use disorder (including 
alcohol are at elevated risk for failure of opioid analgesic therapy to 
achieve the goals of improved comfort and function, and also are at 
high risk for experience harm from therapy, since exposure to 
addictive substances often is a powerful trigger of relapse. Therefore, 
treatment of a patient who has a history of substance use disorder 
should, if possible, involve consultation with an addiction specialist 
before opioid therapy is initiated (and follow-up as needed).   
 Patients who have an active substance use disorder should not receive 
opioid therapy until they are established in a treatment/recovery 
program or alternatives are established such as co-management with 
an addiction professional.  
Confirm 
information 
 Information provided by the patient is a necessary but insufficient part 
of the evaluation process. Reports of previous evaluations and 
treatments should be confirmed by obtaining records from other 
providers, if possible.  
 If possible, the patient evaluation should include information form 
family members and/or significant others. 
 Where available, the state prescription drug monitoring program 
(PDMP) should be consulted to determine whether the patient is 
receiving prescriptions from any other physicians, and the results 
obtained from the PDMP should be documented in the patient record. 
 
 
 
 The goals of pain treatment include reasonably attainable improvement 
in pain and function, improvement in pain-associated symptoms such 
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as sleep disturbances, depression, and anxiety; and avoidance of 
unnecessary or excessive use of medications. 
 The treatment plan and goals should be established as early as possible 
in the treatment process and revisited regularly, so as to provide clear-
cut, individualized objectives to guide the choice of therapies. The 
treatment plan should contain information supporting the selection of 
therapies, both pharmacologic (including medications other than 
opioids) and nonpharmacologic. It also should specify the objectives 
that will be used to evaluate treatment progress, such as relief of pain 
and improved physical ad psychosocial function.  
 The plan should document any further diagnostic evaluations, 
consultations or referrals, or additional therapies that have been 
considered.  
Written 
informed 
consent 
 Informed consent documents typically address: 
o The potential risks and anticipated benefits of chronic opioid 
therapy 
o Potential side effects (both short- and long-term) of the 
medications, such as constipation and cognitive impairment 
o The likelihood that tolerance to and physical dependence on 
the medication will develop 
o The risk of drug interactions and over-sedation 
o The risk of impaired motor shills (affecting driving and other 
tasks) 
o The risk of opioid misuse, dependence, addiction, and overdose 
o The limited evidence as to the benefit of long-term opioid 
therapy 
o The physician’s prescribing policies and expectations, 
including the number and frequency of prescription refills, as 
well as the physician’s policies on early refills and replacement 
of lost or stolen medications 
o Specific reasons for which drug therapy may be changed or 
discontinued (including violation of the policies and 
agreements spelled out in the treatment agreement) 
Written 
treatment 
agreement 
 Treatment agreements outline the joint responsibilities of physician 
and patient and are indicated for opioid or other abusable medications. 
They typically discuss: 
o The goals of treatment, in terms of pain management, 
restoration of function, and safety 
o The patient’s responsibility for safe medication use (e.g., by 
not using more medication than prescribed or using the opioid 
in combination with alcohol or other substances; storing 
medications in secure location; and safe disposal of any unused 
medication) 
o The patient’s responsibility to obtain his or her prescribed 
opioids from only one physician or practice 
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o The patient’s agreement to period drug testing (as of blood, 
urine, hair, or saliva) 
o The physician’s responsibility to be available or to have a 
covering physician available to care for unforeseen problems 
and to prescribe scheduled refills.  
Opioid trial  Generally, safer alternative treatments should be considered before 
initiation opioid therapy for chronic, non-malignant pain. Opioid 
therapy should be presented to the patient as a therapeutic trial or test 
for a defined period of time (usually no more than 90 days) and with 
specified evaluation points. The physician should explain the progress 
will be carefully monitored for both benefit and harm in terms of 
events or risk to safety.  
 When initiated opioid therapy, the lowest dose possible should be 
given to an opioid naïve patient and titrate to affect. A decision to 
continue opioid therapy beyond the trial period should reflect a careful 
evaluation of benefit versus adverse events and/or potential risks.  
Ongoing 
monitoring  
 
 The physician should regularly review the patient’s progress, including 
any new information about the etiology of the pain or the patient’s 
over health and level of function. 
 When possible, collateral information about the patient’s response to 
opioid therapy should be obtained from family members or other close 
contacts, and the state PDMP. 
 The patient should be seen more frequently while the treatment plan is 
being initiated and the opioid dose adjusted. 
 As the patient is stabilized in the treatment regimen, follow-up visits 
may be schedule less frequently.  
 At each visit, the results of chronic opioid therapy should be 
monitored by assessing what have been called the “5 As” of chronic 
pain management; these involve a determination of whether the patient 
is experiencing a reduction in pain (Analgesia), has demonstrated an 
improvement in level of function (Activity), whether there are 
significant Adverse effects, whether there is evidence of Aberrant 
substance-related behaviors, and mood of the individual (Affect) 
 Validated brief assessment tools that measure pain and function, such 
as the three question “Pain, Enjoyment and General Activity” (PEG) 
scale or other validated assessment tools, may be helpful and time 
effective 
Adapting 
treatment 
plan 
 Continuation, modification or termination of opioid therapy for pain 
should be contingent on the physician’s evaluation of 1) evidence of 
the patient’s progress toward treatment objectives and 2) the absence 
of substantial risks of adverse events such as overdose or diversion. 
Periodic drug 
testing 
 Periodic drug testing may be useful in monitoring adherence to the 
treatment plan, as well as in detecting the use of non-prescribed drugs. 
Drug testing is an important monitoring tool because self-reports of 
medication use is not always reliable and behavioral observations may 
detect some problems but not others 
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 Patients being treated for addiction should be tested as frequently as 
necessary to ensure therapeutic adherence, but for patients being 
treated for pain, clinical judgement trumps recommendations for 
frequency of testing. 
 Urine may be the preferred biologic specimen for testing because of its 
ease of collection and storage and the cost-effectiveness of such 
testing. 
 Physicians need to be aware of the limitations of available tests (such 
as their limited sensitivity for many opioids) and take care to order 
tests appropriately. For example, when a drug test is ordered, it is 
important to specify that it include the opioid being prescribed. 
Because of the complexities involved in interpreting drug test results, 
it is advisable to confirm significant or unexpected results with the 
laboratory toxicologist or a clinical pathologist. 
 Test results that suggest opioid misuse should be discussed with the 
patient. It is helpful to approach such a discussion in a positive, 
supportive fashion, so as to strengthen the physician-patient 
relationship and encourage healthy behaviors (as well as behavioral 
change where that is needed). Both the test results and subsequently 
discussion with the patient should be documented in the medical 
record.  
Pill counting  Periodic pill counting is also a useful strategy to confirm medication 
adherence and to minimize diversion (e.g., selling sharing, or giving 
away medications). 
PDMP  As noted earlier and where available, consulting the state’s PDMP 
before prescribing opioids for pain and during ongoing use is highly 
recommended. A PDMP can be useful in monitoring compliance with 
the treatment agreement as well as identifying individuals obtaining 
controlled substances from multiple prescribers. 
Consultation 
and referral 
 The treating physician should seek a consultation with, or refer the 
patient to, a pain, psychiatry, addiction or mental health specialist as 
needed.  
 Physicians who prescribe chronic opioid therapy should be familiar 
with treatment options for opioid addiction (including those available 
in licensed opioid treatment programs) and those offered by an 
appropriately credentialed and experienced physician through office-
based opioid treatment, so as to make appropriate referrals when 
needed 
Discontinuing 
opioid 
therapy 
 Reasons for discontinuing opioid therapy include resolution of the 
underlying painful condition, emergence of intolerable side effects, 
inadequate analgesic effect, failure to improve the patient’s quality of 
life despite reasonable titration, deteriorating function, or significant 
aberrant medication use 
 If opioid therapy is discontinued, the patient who has become 
physically dependent should be provided with a safely structured 
tapering regimen. Withdrawal can be managed either by the 
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prescribing physician or by referring the patient to an addiction 
specialist.  
 The termination of opioid therapy should not mark the end of 
treatment which should continue with other modalities, either through 
direct care or referral to other health care specialists as appropriate 
Medical 
records 
 Every physician who treats patients for chronic pain must maintain 
accurate and complete medical records. Information that should appear 
in the medical record includes the following: 
o Copies of the signed informed consent and treatment 
agreement 
o The patient’s medical history 
o Results of the physical examination and all laboratory tests 
o Results of the risk assessment, including results of any 
screening instruments used 
o A description of the treatments provided, including all 
medications prescribed or administered (including the date, 
type, dose and quality) 
o Instructions to the patient, including discussions of risks and 
benefits with the patient and any significant others 
o Results of ongoing monitoring of patient progress (or lack of 
progress) in terms of pain management and functional 
improvement 
o Notes on evaluations by and consultations with specialists 
o Any other information used to support the initiation, 
continuation, revision, or termination of treatment and the steps 
taken in response to any aberrant medication use behaviors. 
These may include actual copies of, or references to, medical 
records of past hospitalizations or treatments of other providers 
o Authorization for release of information to other treatment 
providers 
o The medical record must include all prescription orders for 
opioid analgesics and other controlled substances, whether 
written or telephoned. In addition, written instructions for the 
use of all medications should be given to the patient and 
documented in the record. The name, telephone number, and 
address of the patient’s pharmacy also should be recorded to 
facilitate contact as needed. Records should be up-t-date and 
maintained in an accessible manner so as to be readily 
available for review. 
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Appendix B 
Cover Letter for Survey 
Dear Participant, 
 I invite you to participate in a research study entitled: Nurse Practitioner use of guidelines 
when initiating and managing chronic pain with opioids in the primary setting.  I am currently 
enrolled in the Family Nurse Practitioner Program at the University of Alaska in Anchorage in 
Anchorage, Alaska, and am in the process of writing my Master’s Project.  The purpose of the 
research is to determine how Nurse Practitioners in Alaska are following recommended 
guidelines when managing chronic pain with opioids in the primary setting, as well as 
identifying barriers to following guidelines.   
 Your participation in this research project is completely voluntary.  Consent for 
participation will be implied with the completion and return of this survey.  You may decline 
altogether, or leave blank any questions you don’t wish to answer.  There are no known risks or 
benefits to participation beyond those encountered in everyday life.  Your responses will remain 
confidential and anonymous.  No identifying information will be collected. Data from this 
research will be kept under lock and key and reported only as a collective combined total.  No 
one other than the researchers will know your individual answers to this questionnaire. 
 If you agree to participate in this project, please answer the questions on the 
questionnaire as best you can.  It should take approximately 10 minutes to complete.  Please 
return the questionnaire by August 31, 2015 in the enclosed preaddressed and stamped envelope.   
If you have any questions about this project, feel free to contact Stephanie Klein, RN, BSN, 
FNP-S.    
Thank you for your assistance in this important endeavor. 
Sincerely yours, 
Stephanie Klein, RN, BSN, OCN, FNP-S 
907-521-2134 
smgregg@alaska.edu 
Principal Investigator 
 
Dr.  Elizabeth Driscoll, PhD, FNP-C 
907-786-4594 
Project Chair Person 
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Appendix C 
 
Survey Tool 
 
For the following questions, please put in blanks or check the box which best fits your response: 
 
1. What is your age in years?  
 
2. How many years have you been practicing as a licensed Nurse Practitioner? 
 
3. In what region of the state do you practice? 
 Anchorage Fairbanks  Juneau Far North 
 Interior South Central   Southeast Southwest 
 
4. Is your practice setting: 
  On the road system  Off the road system 
 
5. What is your primary area of practice? Please select all that apply. 
☐Primary adult care 
☐Primary pediatric care  
☐Primary family care 
☐Emergency/Urgent care  
☐Pain specialty 
☐Oncology 
☐Hospice/Palliative Care  
☐Other, please list: 
 
 
If you selected pain specialty, oncology or hospice/palliative care, please STOP and return 
survey in preaddressed and stamped envelope.  Thank you for your time and participation.   
 
6. Do you prescribe opioids to manage chronic pain in your practice?  
☐Yes ☐No 
 If you answered no, please skip to part B. 
 
Part A. 
For the following questions, please check the box which best fits your 
answer: 
A
lw
ay
s 
A
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s 
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A
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N
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When Initiating opioid therapy for chronic pain, how often do you: 
1. Obtain a thorough medical history?      
2. Obtain a thorough mental health history?       
3. Assess for history of substance abuse?      
4. Assess for contraindications and risks of initiating therapy?      
5. Obtain written informed consent?      
6. Obtain a written treatment agreement?      
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7. Review patient history using the Alaska Prescription Drug 
Monitoring Program? 
     
8. Initiate an opioid trial with specific goals?      
 
 
For the following questions, please check the box which best fits your 
answer: 
A
lw
ay
s 
A
lm
os
t a
lw
ay
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m
et
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A
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N
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When Managing chronic pain with opioid therapy, how often do you: 
9. Perform urine or blood testing for therapy compliance and illicit 
drug use? 
     
10. Count patient’s pills?      
11. Obtain the patient’s prescription history from the Alaska 
Prescription Drug Monitoring Program? 
     
12. Assess results of chronic opioid therapy using the “5 A’s” 
(Analgesia, Activity, Adverse effects, Aberrant substance-related 
behavior and Affect)? 
     
13. Monitor for need or ability to discontinue therapy?      
14. Provide thorough documentation of opioid use and therapy 
outcomes including: all prescription orders and written 
instructions for use, medical history, exam and lab history, risk 
assessment results, treatment descriptions, instructions given to 
patient, notes on evaluations and consultations with specialists, 
and authorization for release of information to other treatment 
providers? 
     
15. Refer for consultation from a pain, psychiatric, addiction or other 
specialist? 
     
 
 
Part B. 
16. Which barriers prevent providers from following current guidelines? (please check all boxes that 
apply): 
☐Unaware of current guidelines 
☐Unaware of Prescription Drug Monitoring Program 
☐Unaware of how to access/use Prescription Drug Monitoring Program 
☐Not enough time during visit 
☐Inadequate patient insurance  
☐Fear of patient going to a different provider 
☐Lack of confidence in addressing potential prescription drug abuse 
☐Feel unqualified to address 
☐Unsure of when to refer to specialist 
☐No patient access to local specialist due to location  
☐Other barriers please list: 
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Optional: Provide any additional thoughts you may have about managing chronic pain with opioids.   
 
 
 
 
 
 
 
 
Once complete, please return survey in the provided pre-stamped and addressed envelope within 2 weeks.  My 
sincerest thank you for taking time out of your day to complete this survey. 
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Appendix D 
 
Flyer for Providers 
 
Chronic Pain Management Resources 
 Federation of State Medical Boards Model Policy 
  Alaska Board of Nursing Endorsed Policy 
http://www.fsmb.org/Media/Default/PDF/FSMB/Advocacy/pain_policy_july2013.pdf 
 
 Alaska’s Prescription Drug Monitoring Program resources 
  Where to create account and log in 
https://alaska.pmpaware.net/login 
  Brochure with contact information with questions 
https://www.commerce.alaska.gov/web/portals/5/pub/PHA_HealthCareProvider_2016.pdf 
  State of Alaska page with user guide and additional resources 
https://www.commerce.alaska.gov/web/cbpl/ProfessionalLicensing/BoardofPharmacy/PrescriptionDrug
MonitoringProgram.aspx 
 
 Chronic Pain Management with Opioids Education Resources 
  Centers for Disease Control 
http://www.cdc.gov/drugoverdose/pdf/guidelines_factsheet‐a.pdf 
http://www.cdc.gov/drugoverdose/pdf/pdo_checklist‐a.pdf 
  American College of Physicians 
https://www.acponline.org/meetings‐courses/focused‐topics/program‐for‐safe‐opioid‐prescribing‐now‐available‐
earn‐free‐cme 
  National Institute of Health 
https://www.drugabuse.gov/opioid‐pain‐management‐cmesces 
  Substance Abuse and Mental Health Services Administration‐supported CME 
http://www.samhsa.gov/medication‐assisted‐treatment/training‐resources/opioid‐courses 
  PainEDU 
https://www.painedu.org/index.asp 
